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Introduction: Pulmonary mycobacterial diseases describe both tuberculosis (TB) and nontu-
berculous mycobacteria (NTM). TB is an established public health issue and a reportable
disease. Efforts in treatment and surveillance have resulted in the incidence of TB to
decrease in recent years. However, the incidence of NTM is increasing, classifying NTM
as an emerging public health problem in the US. Despite the increasing importance of pul-
monary mycobacterial diseases, few data are available measuring the cost burden of myco-
bacterial diseases at the national level. The purpose of this study was to evaluate the cost
burden and measure emerging trends in hospitalization of pulmonary TB and NTM in the
US from 2001 through 2012.
Methods: This study was a retrospective community-based cost analysis of hospitalized
patients with a principal diagnosis of pulmonary mycobacterial diseases from 2001 through
2012. Data for pulmonary TB and NTM were retrieved from the Healthcare Cost and Utili-
zation Project (HCUP), US Department of Health and Human services. Data included in this
analysis were national hospital costs, payer sources, hospital lengths of stay, in-hospital
mortality, and discharge information. The statistical significance of observed trends of
NTM and TB national hospital costs were calculated using Poisson log-linear regression.
National hospital costs for NTM and TB were projected in relation to health care inflation
for each year. A regression model was applied to test the correlation between historic and
projected national hospital costs.
Results: From a total of 36,484,846 admissions, 20,049 hospital admissions were reported for
pulmonary NTM and 69,257 for pulmonary TB in the US from 2001 through 2012. The total
associated costs of these admissions was $1,337,939,745,325, an estimated $970,643,222 of
which was directly associated with pulmonary NTM and $3,390,013,793 for pulmonary TB.
During the study period, the national hospital costs of pulmonary NTM increased at a sta-
tistically significant rate in the US over each year (P = 0.001). A linear regression analysis
demonstrated a high degree of correlation between NTM historic and projected national
hospital costs (R = 0.938, P < 0.001). However, no such correlation between historic and pro-
jected national hospital costs was found for pulmonary TB (R = 0.284, P = 0.372).
Conclusions: The total estimated cost of inpatient care of pulmonary NTM in the US during
the study period was almost $1 billion. The cost of NTM management year after year isM/C 719,
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pulmonary TB national hospital costs were decreasing during the study period. These
trends emphasize the considerable and increasing burden of pulmonary NTM in the US.
Given that the majority of patients with pulmonary NTM are never admitted to the hospi-
tal, the total economic burden of this disease is tremendously higher than measured in this
study. These results emphasize the importance of continued research of pulmonary NTM
in order to improve current guidelines in prevention and treatment strategies.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.
